Laser for retina disease goes to trial

Article

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

The prospective study, being conducted at King's College, University of London, enrolled 18 patients (29 eyes). All patients received treatments with the Ellex 2RT prototype laser and received follow-up examinations at three, six and 12-months.

At three months, the majority of patients demonstrated improvements in VA and central macular thickness (CMT), as measured by optical coherence tomography. CMT decreased in 55% of eyes and remained stable in 24%. An increase in CMT was seen in just 20% of eyes. Furthermore, micro-perimetry confirmed that there was no damage to photoreceptor cells.

Ellex now plans to conduct trials to determine whether the 2RT has potential as an early stage therapy for retinal diseases.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.